ACTU - ACTUATE THERAPEUTICS, INC.
IEX Last Trade
8.32
0.065 0.781%
Share volume: 534
Last Updated: Thu 26 Dec 2024 08:16:11 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$8.26
0.07
0.79%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
10.25%
1 Month
-16.33%
3 Months
24.05%
6 Months
-12.54%
1 Year
-12.54%
2 Year
-12.54%
Key data
Stock price
$8.32
DAY RANGE
$7.43 - $8.26
52 WEEK RANGE
$6.55 - $10.16
52 WEEK CHANGE
-$12.54
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Daniel M. Schmitt
Region: US
Website: actuatetherapeutics.com
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: actuatetherapeutics.com
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
We are a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We were incorporated in Delaware on January 16, 2015, as Apotheca Therapeutics, Inc. and changed our name to Actuate Therapeutics, Inc. on October 1, 2015. Our principal executive offices are located at 1751 River Run, Suite 400, Fort Worth, Texas.
Recent news